123 related articles for article (PubMed ID: 16024990)
1. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing.
Löwe A; Balzer T; Hirt U
Invest Radiol; 2005 Aug; 40(8):521-5. PubMed ID: 16024990
[TBL] [Abstract][Full Text] [Related]
2. Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value.
Emerson J; Kost G
Arch Pathol Lab Med; 2004 Oct; 128(10):1151-6. PubMed ID: 15387706
[TBL] [Abstract][Full Text] [Related]
3. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
Runge VM; Armstrong MR; Barr RG; Berger BL; Czervionke LF; Gonzalez CF; Halford HH; Kanal E; Kuhn MJ; Levin JM; Low RN; Tanenbaum LN; Wang AM; Wong W; Yuh WT; Zoarski GH
Invest Radiol; 2001 Feb; 36(2):65-71. PubMed ID: 11224753
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays.
Proctor KA; Rao LV; Roberts WL
Am J Clin Pathol; 2004 Feb; 121(2):282-92. PubMed ID: 14983944
[TBL] [Abstract][Full Text] [Related]
5. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
Bauner KU; Reiser MF; Huber AM
Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
[TBL] [Abstract][Full Text] [Related]
6. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
Runge VM
Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
[TBL] [Abstract][Full Text] [Related]
7. Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method.
Kang HP; Scott MG; Joe BN; Narra V; Heiken J; Parvin CA
Clin Chem; 2004 Apr; 50(4):741-6. PubMed ID: 14962999
[TBL] [Abstract][Full Text] [Related]
8. Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: prediction with a computer model.
Merkle EM; Dale BM; Barboriak DP
Acad Radiol; 2007 Jul; 14(7):795-803. PubMed ID: 17574130
[TBL] [Abstract][Full Text] [Related]
9. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
[TBL] [Abstract][Full Text] [Related]
10. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
Abujudeh HH; Kosaraju VK; Kaewlai R
AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
[TBL] [Abstract][Full Text] [Related]
11. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
12. Gadobenate dimeglumine (MultiHance) in MR angiography: an in-vitro phantom comparison with gadopentetate dimeglumine (Magnevist) at different concentrations.
Johansson L; Kirchin MA; Ahlström H
Acta Radiol; 2012 Dec; 53(10):1112-7. PubMed ID: 23081961
[TBL] [Abstract][Full Text] [Related]
13. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
Aran S; Shaqdan KW; Abujudeh HH
Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
15. Interference of gadolinium-based contrast agents on colorimetric calcium assays.
Yan R; Tarr H; McNally M; Cartier LJ; Chen Y
Clin Biochem; 2014 May; 47(7-8):648-53. PubMed ID: 24365398
[TBL] [Abstract][Full Text] [Related]
16. Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage.
Colosimo C; Ruscalleda J; Korves M; La Ferla R; Wool C; Pianezzola P; Kirchin MA
Invest Radiol; 2001 Feb; 36(2):72-81. PubMed ID: 11224754
[TBL] [Abstract][Full Text] [Related]
17. Neurotolerability of contrast agents in rats with brain ischemia induced by transient middle cerebral artery occlusion: EEG evaluation.
Frigeni V; Miragoli L; Grotti A; Lorusso V
Invest Radiol; 2001 Jan; 36(1):1-8. PubMed ID: 11176255
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.
Rubin DL; Desser TS; Semelka R; Brown J; Nghiem HV; Stevens WR; Bluemke D; Nelson R; Fultz P; Reimer P; Ho V; Kristy RM; Pierro JA
J Magn Reson Imaging; 1999 Feb; 9(2):240-50. PubMed ID: 10077020
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic impact of falsely decreased calcium values caused by gadoversetamide interference.
Gandhi MJ; Narra VR; Brown JJ; Guo A; Grosu DS; Parvin CA; Scott MG
AJR Am J Roentgenol; 2008 Mar; 190(3):W213-7. PubMed ID: 18287415
[TBL] [Abstract][Full Text] [Related]
20. Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media.
Runge VM; Dickey KM; Williams NM; Peng X
Invest Radiol; 2002 Jul; 37(7):393-8. PubMed ID: 12068161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
